MULTI-YEAR SALES AGREEMENT WITH CHINA FOR ITS
GROUND-BREAKING HeartVue™ 6S SYSTEM TECHNOLOGY.
Deliveries Of The Company's
Non-Invasive Heart Screening System Are Expected To
Exceed $ 50 Million USD.
Palm Beach Gardens , Fla.
, Business Wire, February 9th, 2006 Pegasus/Heartview
LLC (Symbol: PGUZ-OTC) today announced that
it has signed a sales agreement to market and distribute
its HeartVue™ 6S System in China and southern Asia
through the Pegasus PharmGroup and its marketing subsidiary,
Pegasus Lifecare Inc.
Pegasus PharmGroup is a private,
Richmond , B.C., Canada-based corporation which is
not affiliated in any way with Pegasus Pharmaceuticals
Inc. of Palm Beach Gardens , Florida . The exclusive
sales agreement between the two companies covers a
ten year period and includes the sales of a minimum
1,000 HeartVue™ 6S SystemsT per year for a cumulative
total of 10,000 units or $ 50 million USD, focusing on
the more than 20,000 major hospitals throughout China
in concert with Pegasus Lifecare Inc. which has an extensive
distributor network in China and southern Asia.
The HeartVue™ 6S System is an
advanced screening technology for early, non-invasive
screening of heart disease. The technology uses only
4 limb wires (6 standard ECG leads) from the patient's
wrists and ankles. The device includes proprietary
software that converts the electric conductivity of
the cardiac tissue into a three dimensional color-coded
visual portrait, which is simple for physicians to interpret.
The ECV device allows testers to observe the condition
of the heart muscle as well as the intensity of the heart
stress load. The device immediately provides a portrait
of the patient's heart and an electrocardiogram, the
mainstay in the screening of acute and chronic heart
Pegasus Pharmaceuticals Inc...
of Palm Beach Gardens , Florida acquired a majority
interest in Heartview LLC, ( Cleveland , Ohio ), which
holds the worldwide patent, manufacturing and marketing
rights of the HeartVue™ 6S
System. An earlier version of this screening system has
already been cleared for sale in Europe and there is
a patent pending for the ECV device in the United States
For more information,
please contact Mr. Daniel P. Kesonen, Chairman & CEO
of Pegasus Pharmaceuticals Inc., Palm Beach Gardens ,
Florida : (561) 626-9901. Email: email@example.com.
Further corporate news may be viewed on the Company's
new website: www.pegasusbiosciences.com
Safe Harbor :
release may include forward-looking statements within
the meaning of Section 27A of the United States Securities
Act of 1933, as amended, and Section 21E of the United
states Securities and Exchange Act of 1934, as amended
with respect to achieving corporate objectives, developing
additional project interests, the Company's analysis
of opportunities in the acquisition and development
of various project interests and certain other matters.
These statements are made under the 'safe
harbor' provisions of the United States Private Securities
Litigation Reform Act of 1995 and involve risks and
uncertainties which could cause actual results to differ
materially from those in the forward-looking statements